T Cell Receptor Immunotherapy Targeting HPV-16 E6 for HPV-Associated Cancers

NCT02280811 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

12

Enrollment

NIH

Sponsor class

Conditions

Vaginal Cancer
Cervical Cancer
Anal Cancer
Penile Cancer
Oropharyngeal Cancer

Interventions

DRUG: Fludarabine
DRUG: Cyclophosphamide
BIOLOGICAL: E6 TCR
DRUG: Aldesleukin

Sponsor

National Cancer Institute (NCI)